

Green = significant after correction

Red = significant **before** correction only

1.1. Table S1: Association between Exposure to IPV and Child Immune Status

Maternal Exposure to IPV	Outcome	N	Outcome, 75th Percentile v. 25th Percentile									
Unadjusted					Adjusted							
			Predicted Outcome no Exposure	Predicted Outcome with Exposure	Coefficient (95% CI)	P-value	FDR Corrected P-value	Predicted Outcome no Exposure	Predicted Outcome with Exposure	Coefficient (95% CI)	P-value	FDR Corrected P-value
Exposure to IPV during pregnancy	Sum score of inflammation Year 1	270	0.1	0.07	-0.03 (-0.31, 0.24)	0.82	0.96	0.01	0.01	0.01 (-0.29, 0.3)	0.97	0.97
	Ln Th1/Th2 Year 1	268	0.13	0.21	0.08 (-0.06, 0.23)	0.25	0.66	-0.08	-0.01	0.07 (-0.07, 0.21)	0.34	0.77
	Ln Th1/Th17 Year 1	262	0.35	0.49	0.14 (-0.01, 0.28)	0.06	0.66	0.2	0.37	0.17 (0.02, 0.32)	0.03	0.51
	Ln Th1/IL-10 Year 1	269	1.08	1.12	0.04 (-0.09, 0.17)	0.55	0.91	1.05	1.12	0.07 (-0.06, 0.21)	0.31	0.74
	Ln Th2/IL-10 Year 1	269	0.97	0.93	-0.04 (-0.22, 0.13)	0.65	0.91	1.18	1.2	0.02 (-0.16, 0.2)	0.8	0.89
	Ln Th17/IL-10 Year 1	263	0.73	0.62	-0.11 (-0.3, 0.08)	0.26	0.66	0.71	0.63	-0.09 (-0.28, 0.11)	0.4	0.78
	Ln GM-CSF/IL-10 Year 1	270	1.75	1.56	-0.19 (-0.46, 0.07)	0.15	0.66	1.79	1.71	-0.08 (-0.33, 0.17)	0.53	0.8
	Ln IL-2/IL-10 Year 1	265	-2.59	-2.81	-0.23 (-0.59, 0.14)	0.22	0.66	-2.8	-2.97	-0.16 (-0.53, 0.21)	0.4	0.78
	Ln IFN-γ Year 1	270	2.07	2.1	0.03 (-0.11, 0.18)	0.67	0.91	1.89	1.97	0.09 (-0.07, 0.24)	0.29	0.74
	Ln CRP Year 1	244	0.1	0.58	0.49 (-0.05, 1.02)	0.07	0.66	0.23	0.36	0.13 (-0.44, 0.71)	0.66	0.88
	Ln AGP Year 1	241	-0.08	0.02	0.1 (-0.03, 0.22)	0.12	0.66	0.14	0.25	0.11 (-0.03, 0.24)	0.12	0.73
	Ln IGF-1 Year 1	242	3.43	3.43	0 (-0.19, 0.19)	1	1	3.26	3.3	0.04 (-0.17, 0.24)	0.75	0.88
	Sum score of inflammation Year 2	352	0.01	-0.23	-0.24 (-0.48, 0)	0.05	0.66	0.04	-0.12	-0.16 (-0.4, 0.08)	0.2	0.74
	Ln Th1/Th2 Year 2	350	-0.06	-0.01	0.05 (-0.08, 0.18)	0.43	0.9	-0.03	0.1	0.13 (-0.01, 0.28)	0.07	0.62
	Ln Th1/Th17 Year 2	347	0.51	0.49	-0.03 (-0.14, 0.09)	0.67	0.91	0.52	0.57	0.05 (-0.08, 0.17)	0.46	0.78
	Ln Th1/IL-10 Year 2	348	1.45	1.48	0.03 (-0.11, 0.18)	0.67	0.91	1.35	1.43	0.09 (-0.06, 0.23)	0.26	0.74
	Ln Th2/IL-10 Year 2	347	1.49	1.45	-0.04 (-0.2, 0.12)	0.67	0.91	1.3	1.31	0.01 (-0.15, 0.17)	0.89	0.94
	Ln Th17/IL-10 Year 2	343	0.93	0.98	0.05 (-0.11, 0.21)	0.59	0.91	0.97	1.07	0.1 (-0.06, 0.26)	0.23	0.74
	Ln GM-CSF/IL-10 Year 2	348	2.37	2.39	0.02 (-0.23, 0.27)	0.88	0.96	2.33	2.44	0.1 (-0.15, 0.36)	0.44	0.78
	Ln IL-2/IL-10 Year 2	339	-2.28	-2.36	-0.08 (-0.39, 0.23)	0.63	0.91	-2.36	-2.42	-0.06 (-0.41, 0.29)	0.75	0.88
	Ln IFN-γ Year 2	352	1.96	1.85	-0.11 (-0.27, 0.04)	0.13	0.66	1.97	1.91	-0.06 (-0.23, 0.11)	0.47	0.78
Exposure to IPV during first year of child's life	Ln CRP Year 2	737	-0.14	-0.25	-0.11 (-0.35, 0.13)	0.38	0.86	-0.31	-0.41	-0.11 (-0.37, 0.16)	0.44	0.78
	Ln AGP Year 2	457	-0.19	-0.22	-0.03 (-0.14, 0.07)	0.55	0.91	-0.24	-0.25	-0.01 (-0.01, -0.01)	0	0
	Ln IGF-1 Year 2	364	3.82	3.81	-0.01 (-0.13, 0.11)	0.91	0.96	3.9	3.94	0.04 (-0.08, 0.16)	0.53	0.8
	Sum score of inflammation Year 1	279	0.07	0.11	0.04 (-0.19, 0.27)	0.74	0.99	-0.03	0.05	0.07 (-0.18, 0.33)	0.59	0.99
	Ln Th1/Th2 Year 1	276	0.14	0.11	-0.03 (-0.15, 0.09)	0.67	0.99	-0.07	-0.06	0.01 (-0.11, 0.14)	0.83	0.99
	Ln Th1/Th17 Year 1	270	0.38	0.37	-0.01 (-0.13, 0.11)	0.88	0.99	0.23	0.27	0.05 (-0.09, 0.19)	0.53	0.99
	Ln Th1/IL-10 Year 1	278	1.1	1.12	0.02 (-0.09, 0.13)	0.74	0.99	1.06	1.11	0.04 (-0.07, 0.15)	0.47	0.99
	Ln Th2/IL-10 Year 1	277	0.99	1.05	0.06 (-0.09, 0.21)	0.44	0.99	1.28	1.31	0.03 (-0.12, 0.18)	0.7	0.99
	Ln Th17/IL-10 Year 1	271	0.71	0.72	0.01 (-0.14, 0.16)	0.91	0.99	0.79	0.78	-0.01 (-0.16, 0.15)	0.93	0.99
	Ln GM-CSF/IL-10 Year 1	279	1.81	1.84	0.04 (-0.18, 0.26)	0.77	0.99	2.08	2.06	-0.02 (-0.24, 0.2)	0.87	0.99
	Ln IL-2/IL-10 Year 1	274	-2.57	-2.59	-0.01 (-0.32, 0.29)	0.93	0.99	-2.73	-2.74	-0.01 (-0.33, 0.3)	0.94	0.99
	Ln IFN-γ Year 1	279	2.06	2.05	-0.02 (-0.14, 0.11)	0.82	0.99	1.85	1.92	0.07 (-0.07, 0.2)	0.35	0.99
	Ln CRP Year 1	254	0.17	0.44	0.27 (-0.14, 0.69)	0.2	0.99	0.22	0.32	0.1 (-0.36, 0.55)	0.69	0.99
	Ln AGP Year 1	250	-0.07	-0.06	0.01 (-0.09, 0.12)	0.83	0.99	0.04	0.06	0.02 (-0.09, 0.14)	0.72	0.99
	Ln IGF-1 Year 1	251	3.42	3.42	0 (-0.16, 0.16)	0.99	0.99	3.28	3.29	0 (-0.18, 0.18)	0.99	0.99
	Sum score of inflammation Year 2	369	-0.06	-0.1	-0.04 (-0.25, 0.17)	0.72	0.91	-0.03	-0.07	-0.04 (-0.24, 0.16)	0.7	0.88

Green = significant after correction

Red = significant **before** correction only

Maternal Exposure to IPV	Outcome	N	Outcome, 75th Percentile v. 25th Percentile									
			Unadjusted					Adjusted				
			Predicted Outcome no Exposure	Predicted Outcome with Exposure	Coefficient (95% CI)	P-value	FDR Corrected P-value	Predicted Outcome no Exposure	Predicted Outcome with Exposure	Coefficient (95% CI)	P-value	FDR Corrected P-value
	Ln Th1/Th2 Year 2	367	-0.04	-0.16	-0.13 (-0.24, -0.02)	0.02	0.66	-0.04	-0.16	-0.12 (-0.24, 0.01)	0.06	0.62
	Ln Th1/Th17 Year 2	363	0.46	0.46	0 (-0.1, 0.1)	0.98	1	0.47	0.5	0.03 (-0.07, 0.14)	0.55	0.8
	Ln Th1/IL-10 Year 2	365	1.46	1.4	-0.07 (-0.19, 0.05)	0.28	0.66	1.36	1.28	-0.07 (-0.2, 0.05)	0.25	0.74
	Ln Th2/IL-10 Year 2	364	1.46	1.48	0.03 (-0.11, 0.16)	0.7	0.91	1.24	1.27	0.03 (-0.1, 0.16)	0.68	0.88
	Ln Th17/IL-10 Year 2	359	0.97	0.88	-0.09 (-0.22, 0.04)	0.17	0.66	0.94	0.86	-0.08 (-0.21, 0.05)	0.24	0.74
	Ln GM-CSF/IL-10 Year 2	365	2.3	2.32	0.02 (-0.19, 0.23)	0.85	0.96	2.33	2.36	0.04 (-0.18, 0.25)	0.76	0.88
	Ln IL-2/IL-10 Year 2	356	-2.32	-2.15	0.17 (-0.09, 0.44)	0.19	0.66	-2.41	-2.18	0.22 (-0.06, 0.51)	0.12	0.73
	Ln IFN-γ Year 2	369	1.94	1.86	-0.08 (-0.21, 0.05)	0.23	0.66	1.93	1.82	-0.11 (-0.25, 0.04)	0.14	0.73
	Ln CRP Year 2	769	-0.1	-0.24	-0.14 (-0.34, 0.07)	0.2	0.66	-0.3	-0.42	-0.12 (-0.34, 0.11)	0.31	0.74
	Ln AGP Year 2	478	-0.21	-0.2	0.02 (-0.07, 0.11)	0.73	0.91	-0.2	-0.19	0.01 (-0.09, 0.12)	0.81	0.89
	Ln IGF-1 Year 2	381	3.83	3.81	-0.01 (-0.11, 0.09)	0.83	0.96	3.91	3.91	0 (-0.09, 0.1)	0.95	0.97
Cumulative lifetime exposure to IPV	Sum score of inflammation Year 2	655	-0.16	-0.04	0.12 (-0.04, 0.27)	0.15	0.41	0.03	0.06	0.04 (-0.04, 0.12)	0.38	0.75
	Ln Th1/Th2 Year 2	652	-0.06	-0.06	0 (-0.08, 0.08)	0.98	0.98	-0.05	-0.04	0.01 (-0.07, 0.1)	0.78	0.94
	Ln Th1/Th17 Year 2	646	0.45	0.47	0.02 (-0.05, 0.1)	0.55	0.73	0.27	0.32	0.06 (-0.02, 0.13)	0.16	0.63
	Ln Th1/IL-10 Year 2	650	1.52	1.44	-0.08 (-0.16, 0.01)	0.07	0.29	1.39	1.37	-0.02 (-0.06, 0.03)	0.44	0.75
	Ln Th2/IL-10 Year 2	648	1.53	1.46	-0.07 (-0.18, 0.03)	0.17	0.41	1.36	1.33	-0.03 (-0.14, 0.07)	0.56	0.85
	Ln Th17/IL-10 Year 2	641	1.03	0.94	-0.1 (-0.2, 0)	0.06	0.29	0.94	0.91	-0.03 (-0.09, 0.02)	0.22	0.67
	Ln GM-CSF/IL-10 Year 2	650	2.19	2.28	0.09 (-0.05, 0.23)	0.23	0.45	2.28	2.39	0.11 (-0.04, 0.26)	0.14	0.63
	Ln IL-2/IL-10 Year 2	641	-2.22	-2.28	-0.06 (-0.26, 0.13)	0.53	0.73	-2.38	-2.42	-0.04 (-0.24, 0.16)	0.69	0.91
	Ln IFN-γ Year 2	655	1.91	1.96	0.05 (-0.04, 0.15)	0.29	0.5	1.93	1.99	0.05 (-0.05, 0.16)	0.33	0.75
	Ln CRP Year 2	1333	-0.09	-0.11	-0.02 (-0.17, 0.13)	0.81	0.97	-0.33	-0.34	-0.01 (-0.17, 0.15)	0.9	0.98
	Ln AGP Year 2	806	-0.21	-0.21	0 (-0.07, 0.07)	0.93	0.98	-0.18	-0.18	0 (-0.07, 0.08)	0.99	0.99
	Ln IGF-1 Year 2	679	3.95	3.84	-0.11 (-0.18, -0.03)	0	0.04	3.93	3.9	-0.03 (-0.07, 0)	0.05	0.63

N is from the unadjusted analyses

Green = significant after correction

Red = significant **before** correction only

1.2. Table S2: Association between Parental Stress and Child Immune Status

Parental Stress	Outcome	N	25th Percentile	75th Percentile	Outcome, 75th Percentile v. 25th Percentile									
					Unadjusted					Adjusted				
					Predicted Outcome at 25th Percentile	Predicted Outcome at 75th Percentile	Coefficient (95% CI)	P-value	FDR Corrected P-value	Predicted Outcome at 25th Percentile	Predicted Outcome at 75th Percentile	Coefficient (95% CI)	P-value	FDR Corrected P-value
Maternal stress score	Sum score of inflammation Year 2	657	10	18	-0.13	-0.07	0.06 (-0.05, 0.18)	0.26	0.88	0.04	0.09	0.05 (-0.06, 0.17)	0.36	0.96
	Ln Th1/Th2 Year 2	654	10	18	-0.05	-0.08	-0.03 (-0.09, 0.03)	0.3	0.88	-0.03	-0.07	-0.03 (-0.09, 0.03)	0.31	0.96
	Ln Th1/Th17 Year 2	648	10	18	0.46	0.47	0.01 (-0.1, 0.11)	0.92	0.99	0.32	0.34	0.03 (-0.08, 0.14)	0.63	0.99
	Ln Th1/IL-10 Year 2	652	10	18	1.48	1.46	-0.03 (-0.09, 0.03)	0.4	0.88	1.37	1.35	-0.01 (-0.08, 0.05)	0.69	0.99
	Ln Th2/IL-10 Year 2	650	10	18	1.49	1.49	0 (-0.08, 0.07)	0.97	0.99	1.35	1.35	0.01 (-0.07, 0.08)	0.89	0.99
	Ln Th17/IL-10 Year 2	643	10	18	0.96	0.99	0.02 (-0.05, 0.1)	0.52	0.96	0.89	0.91	0.02 (-0.07, 0.1)	0.69	0.99
	Ln GM-CSF/IL-10 Year 2	652	10	18	2.23	2.24	0.02 (-0.09, 0.12)	0.78	0.99	2.33	2.33	0 (-0.12, 0.12)	1	1
	Ln IL-2/IL-10 Year 2	643	10	18	-2.32	-2.21	0.11 (-0.1, 0.31)	0.32	0.88	-2.39	-2.41	-0.02 (-0.16, 0.13)	0.82	0.99
	Ln IFN-γ Year 2	657	10	18	1.91	1.94	0.03 (-0.08, 0.13)	0.64	0.99	1.95	1.96	0 (-0.07, 0.08)	0.98	1
	Ln CRP Year 2	1338	10	17	-0.08	-0.12	-0.04 (-0.13, 0.05)	0.4	0.88	-0.32	-0.33	-0.01 (-0.19, 0.17)	0.9	0.99
	Ln AGP Year 2	809	10	18	-0.21	-0.2	0 (-0.05, 0.05)	0.93	0.99	-0.19	-0.18	0.01 (-0.04, 0.06)	0.75	0.99
	Ln IGF-1 Year 2	681	10	18	3.9	3.88	-0.02 (-0.07, 0.03)	0.48	0.96	3.9	3.88	-0.02 (-0.08, 0.04)	0.52	0.99
Paternal stress score	Sum score of inflammation Year 2	481	15	22	-0.04	0.06	0.09 (-0.02, 0.21)	0.11	0.88	0.14	0.2	0.06 (-0.06, 0.18)	0.35	0.96
	Ln Th1/Th2 Year 2	479	15	22	-0.05	-0.06	-0.01 (-0.07, 0.05)	0.74	0.99	-0.01	-0.03	-0.03 (-0.08, 0.03)	0.36	0.96
	Ln Th1/Th17 Year 2	477	15	22	0.49	0.46	-0.03 (-0.09, 0.02)	0.26	0.88	0.35	0.32	-0.03 (-0.09, 0.02)	0.23	0.96
	Ln Th1/IL-10 Year 2	478	15	22	1.51	1.45	-0.06 (-0.17, 0.04)	0.24	0.88	1.39	1.4	0.01 (-0.06, 0.08)	0.81	0.99
	Ln Th2/IL-10 Year 2	477	15	22	1.51	1.5	-0.01 (-0.1, 0.07)	0.76	0.99	1.46	1.48	0.01 (-0.07, 0.1)	0.77	0.99
	Ln Th17/IL-10 Year 2	474	15	22	0.99	0.99	0 (-0.09, 0.09)	0.99	0.99	0.91	0.92	0.01 (-0.07, 0.1)	0.8	0.99
	Ln GM-CSF/IL-10 Year 2	478	15	22	2.15	2.35	0.2 (-0.07, 0.47)	0.14	0.88	2.33	2.55	0.21 (-0.06, 0.48)	0.12	0.96
	Ln IL-2/IL-10 Year 2	470	15	21.75	-2.17	-2.15	0.02 (-0.13, 0.17)	0.8	0.99	-2.49	-2.46	0.03 (-0.11, 0.17)	0.69	0.99
	Ln IFN-γ Year 2	481	15	22	1.97	1.97	0.01 (-0.07, 0.08)	0.87	0.99	2.05	2.04	-0.01 (-0.09, 0.07)	0.82	0.99
	Ln CRP Year 2	966	15	22	-0.2	-0.25	-0.05 (-0.17, 0.06)	0.36	0.88	-0.17	-0.23	-0.06 (-0.18, 0.06)	0.33	0.96
	Ln AGP Year 2	608	15	22	-0.28	-0.24	0.04 (-0.01, 0.09)	0.1	0.88	-0.21	-0.17	0.05 (-0.01, 0.1)	0.09	0.96
	Ln IGF-1 Year 2	497	15	22	3.86	3.87	0.02 (-0.05, 0.08)	0.64	0.99	3.74	3.78	0.04 (-0.01, 0.09)	0.11	0.96

N, 25th Percentile, and 75th Percentile are from the unadjusted analyses

Green = significant after correction

Red = significant **before** correction only

1.3. Table S3: Association between CES-D Scores at Year 1 and Child Immune Status

CES-D Year 1	Outcome	N	25th Percentile	75th Percentile	Outcome, 75th Percentile v. 25th Percentile									
					Unadjusted					Adjusted				
					Predicted Outcome at 25th Percentile	Predicted Outcome at 75th Percentile	Coefficient (95% CI)	P-value	FDR Corrected P-value	Predicted Outcome at 25th Percentile	Predicted Outcome at 75th Percentile	Coefficient (95% CI)	P-value	FDR Corrected P-value
CES-D Score Year 1	Sum score of inflammation Year 1	593	6	16	-0.01	0.01	0.02 (-0.15, 0.2)	0.8	0.88	-0.05	-0.05	0 (-0.1, 0.1)	0.97	0.97
	Ln Th1/Th2 Year 1	588	6	16	0.15	0.17	0.02 (-0.02, 0.07)	0.35	0.65	-0.02	-0.01	0 (-0.05, 0.06)	0.93	0.97
	Ln Th1/Th17 Year 1	583	6	16	0.36	0.47	0.11 (0.01, 0.21)	0.03	0.5	0.31	0.42	0.12 (0.01, 0.22)	0.03	0.62
	Ln Th1/IL-10 Year 1	590	6	16	1.11	1.1	-0.01 (-0.06, 0.05)	0.86	0.88	1.06	1.05	-0.02 (-0.07, 0.04)	0.56	0.97
	Ln Th2/IL-10 Year 1	588	6	16	0.93	0.89	-0.04 (-0.1, 0.03)	0.28	0.65	0.96	0.94	-0.02 (-0.18, 0.13)	0.76	0.97
	Ln Th17/IL-10 Year 1	582	6	16	0.75	0.64	-0.11 (-0.26, 0.04)	0.16	0.65	0.67	0.56	-0.11 (-0.26, 0.04)	0.15	0.62
	Ln GM-CSF/IL-10 Year 1	591	6	16	1.7	1.82	0.12 (-0.11, 0.35)	0.3	0.65	1.96	2.06	0.1 (-0.16, 0.35)	0.47	0.97
	Ln IL-2/IL-10 Year 1	582	6	16	-2.7	-2.61	0.1 (-0.03, 0.22)	0.12	0.65	-2.7	-2.6	0.1 (-0.02, 0.22)	0.12	0.62
	Ln IFN-γ Year 1	593	6	16	2.03	2.04	0.02 (-0.05, 0.08)	0.64	0.88	1.9	1.9	-0.01 (-0.08, 0.07)	0.89	0.97
	Ln CRP Year 1	541	6	16	-0.14	0.04	0.19 (0.01, 0.36)	0.04	0.5	0.15	0.22	0.07 (-0.02, 0.16)	0.13	0.62
	Ln AGP Year 1	528	6	16	-0.12	-0.07	0.05 (-0.03, 0.13)	0.26	0.65	0.09	0.1	0.02 (-0.27, 0.3)	0.92	0.97
	Ln IGF-1 Year 1	527	6	16	3.64	3.6	-0.03 (-0.1, 0.03)	0.35	0.65	3.51	3.58	0.07 (-0.06, 0.2)	0.29	0.8
	Sum score of inflammation Year 2	666	6	16	-0.12	0.01	0.13 (-0.03, 0.29)	0.12	0.7	0.05	0.11	0.06 (-0.3, 0.43)	0.76	0.99
	Ln Th1/Th2 Year 2	663	6	16	-0.05	-0.06	0 (-0.05, 0.04)	0.89	0.93	-0.04	-0.02	0.02 (-0.03, 0.07)	0.47	0.99
	Ln Th1/Th17 Year 2	656	6	16	0.49	0.45	-0.04 (-0.14, 0.06)	0.43	0.79	0.31	0.28	-0.03 (-0.13, 0.08)	0.61	0.99
	Ln Th1/IL-10 Year 2	662	6	16	1.5	1.46	-0.04 (-0.09, 0.02)	0.17	0.7	1.37	1.35	-0.01 (-0.04, 0.01)	0.29	0.99
	Ln Th2/IL-10 Year 2	660	6	16	1.5	1.47	-0.03 (-0.1, 0.03)	0.28	0.7	1.32	1.3	-0.02 (-0.05, 0.02)	0.33	0.99
	Ln Th17/IL-10 Year 2	652	6	16	0.94	0.95	0.01 (-0.13, 0.16)	0.89	0.93	0.87	0.88	0.01 (-1.48, 1.5)	0.99	0.99
	Ln GM-CSF/IL-10 Year 2	662	6	16	2.25	2.24	-0.01 (-0.1, 0.08)	0.8	0.93	2.39	2.38	0 (-0.09, 0.08)	0.94	0.99
	Ln IL-2/IL-10 Year 2	653	6	16	-2.23	-2.26	-0.03 (-0.15, 0.08)	0.59	0.93	-2.43	-2.44	-0.01 (-0.14, 0.11)	0.85	0.99
Binary CES-D Score Year 1	Ln IFN-γ Year 2	666	6	16	1.93	1.92	-0.01 (-0.07, 0.05)	0.81	0.93	1.98	2	0.02 (-0.05, 0.08)	0.6	0.99
	Ln CRP Year 2	1358	6	16	-0.12	-0.07	0.06 (-0.03, 0.14)	0.18	0.7	-0.31	-0.27	0.04 (0, 0.09)	0.06	0.47
	Ln AGP Year 2	824	6	16	-0.22	-0.2	0.02 (-0.01, 0.06)	0.24	0.7	-0.18	-0.16	0.02 (0, 0.04)	0.12	0.69
	Ln IGF-1 Year 2	689	6	16	3.89	3.88	-0.01 (-0.06, 0.04)	0.73	0.93	3.85	3.88	0.02 (-0.06, 0.11)	0.61	0.99
	Sum score of inflammation Year 1	593	0	1	0.01	-0.02	-0.03 (-0.21, 0.15)	0.78	0.88	0.01	-0.02	-0.03 (-0.21, 0.15)	0.78	0.97
	Ln Th1/Th2 Year 1	588	0	1	0.15	0.18	0.03 (-0.05, 0.11)	0.5	0.8	0.15	0.18	0.03 (-0.05, 0.11)	0.5	0.97
	Ln Th1/Th17 Year 1	583	0	1	0.4	0.39	-0.01 (-0.1, 0.08)	0.88	0.88	0.4	0.39	-0.01 (-0.1, 0.08)	0.88	0.97
	Ln Th1/IL-10 Year 1	590	0	1	1.11	1.1	-0.01 (-0.11, 0.08)	0.81	0.88	1.11	1.1	-0.01 (-0.11, 0.08)	0.81	0.97
	Ln Th2/IL-10 Year 1	588	0	1	0.92	0.86	-0.06 (-0.18, 0.05)	0.3	0.65	0.92	0.86	-0.06 (-0.18, 0.05)	0.3	0.8
	Ln Th17/IL-10 Year 1	582	0	1	0.68	0.67	-0.01 (-0.14, 0.11)	0.84	0.88	0.68	0.67	-0.01 (-0.14, 0.11)	0.84	0.97
	Ln GM-CSF/IL-10 Year 1	591	0	1	1.64	1.67	0.03 (-0.14, 0.2)	0.74	0.88	1.64	1.67	0.03 (-0.14, 0.2)	0.74	0.97
	Ln IL-2/IL-10 Year 1	582	0	1	-2.67	-2.58	0.09 (-0.12, 0.31)	0.4	0.69	-2.67	-2.58	0.09 (-0.12, 0.31)	0.4	0.96
	Ln IFN-γ Year 1	593	0	1	2.03	2.05	0.02 (-0.08, 0.11)	0.73	0.88	2.03	2.05	0.02 (-0.08, 0.11)	0.73	0.97
	Ln CRP Year 1	541	0	1	-0.1	0.11	0.2 (-0.11, 0.51)	0.2	0.65	-0.1	0.11	0.2 (-0.11, 0.51)	0.2	0.68

Green = significant after correction

Red = significant **before** correction only

CES-D Year 1	Outcome	N	25th Percentile	75th Percentile	Outcome, 75th Percentile v. 25th Percentile									
					Unadjusted					Adjusted				
					Predicted Outcome at 25th Percentile	Predicted Outcome at 75th Percentile	Coefficient (95% CI)	P-value	FDR Corrected P-value	Predicted Outcome at 25th Percentile	Predicted Outcome at 75th Percentile	Coefficient (95% CI)	P-value	FDR Corrected P-value
	Ln AGP Year 1	528	0	1	-0.11	-0.04	0.07 (-0.02, 0.15)	0.11	0.65	-0.11	-0.04	0.07 (-0.02, 0.15)	0.11	0.62
	Ln IGF-1 Year 1	527	0	1	3.64	3.55	-0.09 (-0.2, 0.03)	0.14	0.65	3.64	3.55	-0.09 (-0.2, 0.03)	0.14	0.62
	Sum score of inflammation Year 2	666	0	1	-0.08	-0.07	0.01 (-0.16, 0.18)	0.93	0.93	0.08	-0.26	-0.35 (-0.66, -0.04)	0.03	0.47
	Ln Th1/Th2 Year 2	663	0	1	-0.06	-0.05	0.01 (-0.08, 0.1)	0.82	0.93	-0.04	0	0.04 (-0.05, 0.13)	0.42	0.99
	Ln Th1/Th17 Year 2	656	0	1	0.46	0.47	0.01 (-0.07, 0.09)	0.79	0.93	0.28	0.34	0.06 (-0.03, 0.15)	0.17	0.82
	Ln Th1/IL-10 Year 2	662	0	1	1.49	1.44	-0.05 (-0.15, 0.05)	0.3	0.7	1.37	1.39	0.01 (-0.15, 0.18)	0.87	0.99
	Ln Th2/IL-10 Year 2	660	0	1	1.5	1.44	-0.06 (-0.18, 0.06)	0.32	0.7	1.31	1.29	-0.03 (-0.14, 0.08)	0.65	0.99
	Ln Th17/IL-10 Year 2	652	0	1	1	0.94	-0.06 (-0.17, 0.06)	0.32	0.7	0.91	0.92	0.01 (-0.35, 0.37)	0.96	0.99
	Ln GM-CSF/IL-10 Year 2	662	0	1	2.26	2.22	-0.03 (-0.2, 0.13)	0.71	0.93	2.39	2.36	-0.03 (-0.2, 0.14)	0.74	0.99
	Ln IL-2/IL-10 Year 2	653	0	1	-2.22	-2.35	-0.13 (-0.35, 0.09)	0.24	0.7	-2.41	-2.54	-0.14 (-0.36, 0.09)	0.23	0.93
	Ln IFN-γ Year 2	666	0	1	1.94	1.89	-0.06 (-0.17, 0.05)	0.32	0.7	2	1.97	-0.02 (-0.14, 0.09)	0.71	0.99
	Ln CRP Year 2	1358	0	1	-0.1	-0.05	0.05 (-0.11, 0.21)	0.56	0.93	-0.35	-0.86	-0.51 (-1.01, -0.01)	0.05	0.47
	Ln AGP Year 2	824	0	1	-0.23	-0.16	0.07 (-0.01, 0.14)	0.07	0.7	-0.18	-0.13	0.06 (-0.08, 0.2)	0.43	0.99
	Ln IGF-1 Year 2	689	0	1	3.9	3.86	-0.04 (-0.12, 0.05)	0.39	0.78	3.88	3.88	0 (-0.08, 0.08)	0.95	0.99

N, 25th Percentile, and 75th Percentile are from the unadjusted analyses

Green = significant after correction

Red = significant **before** correction only

1.4. Table S4: Association between CES-D Scores at Year 2 and Child Immune Status

CES-D Year 2	Outcome	N	25th Percentile	75th Percentile	Outcome, 75th Percentile v. 25th Percentile									
					Unadjusted					Adjusted				
					Predicted Outcome at 25th Percentile	Predicted Outcome at 75th Percentile	Coefficient (95% CI)	P-value	FDR Corrected P-value	Predicted Outcome at 25th Percentile	Predicted Outcome at 75th Percentile	Coefficient (95% CI)	P-value	FDR Corrected P-value
CES-D Score Year 2	Sum score of inflammation Year 2	656	5	17	-0.11	-0.09	0.02 (-0.08, 0.11)	0.73	0.97	0.06	0.09	0.02 (-0.15, 0.19)	0.8	0.97
	Ln Th1/Th2 Year 2	653	5	17	-0.07	-0.06	0.01 (-0.04, 0.05)	0.82	0.97	-0.06	-0.05	0.01 (-0.04, 0.06)	0.72	0.97
	Ln Th1/Th17 Year 2	647	5	17	0.46	0.45	-0.01 (-0.06, 0.05)	0.78	0.97	0.29	0.3	0.01 (-0.04, 0.06)	0.69	0.97
	Ln Th1/IL-10 Year 2	651	5	17	1.48	1.43	-0.05 (-0.18, 0.07)	0.41	0.97	1.37	1.36	-0.01 (-0.13, 0.12)	0.93	0.97
	Ln Th2/IL-10 Year 2	649	5	17	1.53	1.47	-0.07 (-0.15, 0.02)	0.13	0.81	1.37	1.34	-0.02 (-0.1, 0.05)	0.54	0.97
	Ln Th17/IL-10 Year 2	642	5	17	0.99	0.97	-0.01 (-0.15, 0.13)	0.86	0.97	0.9	0.92	0.03 (-0.12, 0.17)	0.73	0.97
	Ln GM-CSF/IL-10 Year 2	651	5	17	2.24	2.23	-0.01 (-0.09, 0.08)	0.91	0.97	2.33	2.34	0.01 (-0.08, 0.09)	0.89	0.97
	Ln IL-2/IL-10 Year 2	642	5	17	-2.18	-2.27	-0.09 (-0.2, 0.02)	0.12	0.81	-2.35	-2.42	-0.07 (-0.19, 0.05)	0.25	0.97
	Ln IFN-γ Year 2	656	5	17	1.94	1.92	-0.02 (-0.09, 0.05)	0.54	0.97	1.97	1.98	0 (-0.06, 0.07)	0.9	0.97
	Ln CRP Year 2	1337	5	17	-0.11	-0.1	0.01 (-0.08, 0.09)	0.85	0.97	-0.32	-0.35	-0.03 (-0.13, 0.06)	0.53	0.97
	Ln AGP Year 2	808	5	17	-0.2	-0.21	0 (-0.04, 0.04)	0.91	0.97	-0.18	-0.19	-0.01 (-0.06, 0.03)	0.64	0.97
	Ln IGF-1 Year 2	680	5	17	3.93	3.86	-0.07 (-0.16, 0.01)	0.1	0.81	3.9	3.89	-0.01 (-0.09, 0.07)	0.86	0.97
Binary CES-D Score Year 2	Sum score of inflammation Year 2	656	0	1	-0.13	-0.03	0.11 (-0.07, 0.28)	0.24	0.94	0.02	0.13	0.12 (-0.07, 0.3)	0.23	0.97
	Ln Th1/Th2 Year 2	653	0	1	-0.06	-0.06	0 (-0.09, 0.09)	0.98	0.98	-0.05	-0.06	-0.01 (-0.11, 0.09)	0.85	0.97
	Ln Th1/Th17 Year 2	647	0	1	0.46	0.45	-0.01 (-0.09, 0.07)	0.85	0.97	0.29	0.3	0.01 (-0.08, 0.1)	0.9	0.97
	Ln Th1/IL-10 Year 2	651	0	1	1.48	1.43	-0.05 (-0.14, 0.05)	0.31	0.97	1.37	1.38	0.02 (-0.09, 0.12)	0.79	0.97
	Ln Th2/IL-10 Year 2	649	0	1	1.51	1.45	-0.06 (-0.18, 0.06)	0.32	0.97	1.36	1.33	-0.03 (-0.15, 0.1)	0.68	0.97
	Ln Th17/IL-10 Year 2	642	0	1	0.99	0.94	-0.05 (-0.16, 0.06)	0.41	0.97	0.91	0.91	0 (-0.12, 0.13)	0.99	0.99
	Ln GM-CSF/IL-10 Year 2	651	0	1	2.24	2.23	-0.01 (-0.17, 0.15)	0.92	0.97	2.33	2.34	0.01 (-0.16, 0.18)	0.92	0.97
	Ln IL-2/IL-10 Year 2	642	0	1	-2.21	-2.34	-0.14 (-0.35, 0.08)	0.21	0.94	-2.36	-2.48	-0.12 (-0.34, 0.11)	0.32	0.97
	Ln IFN-γ Year 2	656	0	1	1.93	1.94	0.01 (-0.1, 0.12)	0.87	0.97	1.94	1.98	0.05 (-0.07, 0.17)	0.43	0.97
	Ln CRP Year 2	1337	0	1	-0.11	-0.09	0.02 (-0.15, 0.18)	0.85	0.97	-0.32	-0.37	-0.05 (-0.23, 0.14)	0.62	0.97
	Ln AGP Year 2	808	0	1	-0.2	-0.21	0 (-0.08, 0.07)	0.93	0.97	-0.18	-0.19	-0.01 (-0.1, 0.08)	0.83	0.97
	Ln IGF-1 Year 2	680	0	1	3.92	3.84	-0.08 (-0.16, 0.01)	0.07	0.81	3.91	3.88	-0.03 (-0.11, 0.05)	0.5	0.97

N, 25th Percentile, and 75th Percentile are from the unadjusted analyses